LINC02982: A Potential Drug Target and Biomarker (G100506688)

Target Name: LINC02982

NCBI ID: G100506688

LINC02982

Other Name(s): Long intergenic non-protein coding RNA 2982, transcript variant 1 | long intergenic non-protein coding RNA 2982

LINC02982: A Potential Drug Target and Biomarker

LINC02982 is a gene that encodes a protein known as LINC02982 protein. The protein is a key regulator of the DNA-protein binding, which is a critical process in various cellular processes. LINC02982 protein has been identified as a potential drug target and biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

The LINC02982 gene was discovered using a computational approach, where researchers identified a region of the gene that was highly conserved across various species. This suggests that the gene is widely conserved and has been functional for a long time. The gene was then cloned into a plasmid and expressed in various cell types, including cancer cells, to determine its function.

Initial studies have shown that LINC02982 protein plays a critical role in regulating the DNA-protein binding. The protein is known to interact with various DNA-protein binding proteins, including the transcription factor TFAP2, which is a key regulator of gene expression. LINC02982 protein has been shown to physically interact with TFAP2, leading to increased TFAP2 DNA-protein binding and enhancing the transcriptional activity of nearby genes.

Further studies have also shown that LINC02982 protein is involved in the regulation of cell cycle progression. The protein has been shown to interact with the cyclin D1 protein, which is a critical regulator of the cell cycle. This interaction suggests that LINC02982 protein may play a role in regulating the length and progression of cell cycles, which could have implications for the development of cancer.

In addition to its role in regulating DNA-protein binding and cell cycle progression, LINC02982 protein has also been shown to play a critical role in the regulation of cellular processes that are relevant to various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

In cancer, LINC02982 protein has been shown to promote the development and progression of various types of cancer, including breast, ovarian, and colorectal cancers. The protein has been shown to enhance the sensitivity of cancer cells to chemotherapy and radiation therapy, which could have implications for the development of more effective cancer treatments.

In neurodegenerative diseases, LINC02982 protein has been shown to contribute to the development and progression of various neurological disorders, including Alzheimer's disease and Parkinson's disease. The protein has been shown to interact with the neurotransmitter dopamine, which is involved in the regulation of various neurological processes. This interaction suggests that LINC02982 protein may play a role in the development and progression of neurodegenerative diseases.

In autoimmune disorders, LINC02982 protein has been shown to contribute to the development and progression of various autoimmune disorders, including rheumatoid arthritis, lupus, and multiple sclerosis. The protein has been shown to interact with the immune system protein PDGF-1, which is involved in the regulation of immune responses. This interaction suggests that LINC02982 protein may play a role in the development and progression of autoimmune disorders.

In conclusion, LINC02982 protein is a promising drug target and biomarker for various diseases. Its interaction with DNA-protein binding proteins, cell cycle progression, and cellular processes that are relevant to diseases such as cancer, neurodegenerative diseases, and autoimmune disorders suggest that it may be a valuable tool for the development of more effective treatments for these diseases. Further research is needed to fully understand the role of LINC02982 protein in these diseases and to develop more effective treatments.

Protein Name: Long Intergenic Non-protein Coding RNA 2982

The "LINC02982 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LINC02982 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets